Coldstream Capital Management
ANIK icon

Coldstream Capital Management’s Anika Therapeutics ANIK Stock Holding History

Coldstream Capital Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-575
Closed -$8.64K – 1227
2025
Q1 		$8.64K Buy
+575
New +$9.57K ﹤0.01% 2444

Other funds holding ANIK

TI
Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Boothbay Fund Management
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AFA
Alta Fundamental Advisers New York $333M AUM 102.25% 1-Year Est. Return

Coldstream Capital Management's ANIK Position: Q2 2025 in Review

Coldstream Capital Management sold out of Anika Therapeutics (ANIK) in Q2 2025, closing a stake of 575 shares — an estimated $8.64K sold.

Coldstream Capital Management first reported a position in ANIK in Q1 2025 and held it in 1 quarter. The position peaked at $8.64K in Q1 2025. 103 funds tracked by Wall St. Rank hold ANIK as of Q2 2025.

  • Coldstream Capital Management reported no remaining Anika Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 575 Anika Therapeutics shares in Q2 2025, an estimated $8.64K.
  • Coldstream Capital Management first reported a position in Anika Therapeutics in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's Anika Therapeutics position peaked at $8.64K in Q1 2025.
  • 103 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.